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Objective: To assess the cost-effectiveness of adding delamanid (Deltyba) to a background
regimen (BR) for treating multidrug-resistant tuberculosis (MDR-TB) in Germany.
Methods: The incremental cost-effectiveness of treating a cohort of MDR-TB patients, 38-years
old on average, with Deltyba plus BR versus a five drug- BR regimen alone was compared in a
Markov model over a period of 10 years. Cost per quality-adjusted life year (QALY) and
disability-adjusted life years (DALY) were determined from a societal perspective. Recent data
from a German cost calculation on MDR-TB were applied to the 24-month outcome results of
patients participating in the placebo-controlled, phase II Otsuka’s Trial 204. Costs and effec-
tiveness were discounted at a rate of 3% and subjected to deterministic as well as probabilistic
sensitivity analysis in a Monte Carlo simulation.
Results: Based on the current market prices the total discounted cost per patient on BR plus
Deltyba was V142,732 compared to V150,909 for BR alone. The total discounted QALYs
per patient were 8.47 for Deltyba versus 6.13 for BR alone. Accordingly, the addition of
Deltyba proved to be dominant over the BR alone-strategy by simultaneously saving V8177
and gaining 2.34 QALYs. Deltyba was cost saving in 73% of probabilistic sensitivity analyses
compared to BR alone and 100% cost effective at a willingness-to-pay (WTP) threshold of
V10,000.
Conclusions: Under conditions prevalent in Germany, Deltyba added to a five drug BR
regimen is likely to be cost-saving compared to BR alone under a wide range of assumptions.
Adding delamanid remained cost-effective when costs due to loss of productivity were
excluded as the QALYs gained by lower lethality and a higher proportion of successfully treatedEpidemiology, University Medical Hospital Schleswig-Holstein, Niemannsweg 11, 24015 Kiel,
ax: þ49 (0) 4315973730.
i-kiel.de (R. Diel).
15.01.017
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Cost-effectiveness of adding Deltyba for MDR-TB treatment 633patients outweighed the delamanid drug costs. These results strongly support the application
of Deltyba in treating MDR-TB patients.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Although worldwide tuberculosis (TB) incidence rates are
decreasing slightly, multidrug-resistant TB (MDR-TB),
defined as simultaneous resistance to at least the most
powerful anti-TB drugs, isoniazid and rifampicin, remains a
major public health challenge in Europe. In 2012, 15 of the
22 countries considered “MDR-TB high burden” belong to
WHO European region [1,2] in which the prevalence of MDR-
TB among 90,127 new TB cases subjected to first-line
testing was 15% [3]. A nearly identical proportion among
the 127 MDR-TB cases tested (14.9%) for second line drugs
were found to be extensively-drug-resistant (XDR-TB),
defined by an additional resistance to at least one fluo-
roquinolone and to one or more of the injectable drugs [3].
In Germany, where the incidence of MDR-TB had remained
stable at approximately 2.2% over the previous decade, an
increase in the absolute cases of MDR-TB, from 65 cases in
2012 to 102 cases in 2013, was observed [4].
Compared to drug-susceptible TB, treatment of MDR-TB
and XDR-TB requires significantly higher resources. This is
due to its longer duration of 20 months and the use of a
number of more costly and potentially toxic drugs. Glob-
ally, it is reported that only 48% of MDR-TB patients receive
successful treatment whilst 28% of cases are reported to be
lost to follow-up on [5]. Thus, new drugs that help to
improve treatment outcomes in a higher proportion of pa-
tients with MDR-TB are urgently needed.
Following positive opinions from the Committee for
Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA), recommending the approval of
delamanid and bedaquiline [6,7] the first novel treatment
to be licensed for use in MDR-TB by the European Com-
mission was bedaquiline (Sirturo) in March 2014. One
month later, in April 2014, marketing authorization was
granted for delamanid (Deltyba) for use as part of an
appropriate combination regimen against pulmonary
multidrug-resistant tuberculosis (MDR-TB) in adult patients
when an effective treatment regimen cannot otherwise be
composed for reasons of resistance or tolerability. The full
course of Deltyba is 24 weeks, preferably under directly
observed conditions (DOT). To date, three consecutive tri-
als of the drug have been completed. These are: 1) a ran-
domized placebo-controlled trial of two months (Trial 204)
of 481 patients; 2) an open-label trial with Deltyba lasting
six months (Trial 208), performed on 213 patients who
completed Trial 204; and 3) a follow-up registry trial (Trial
116) collecting treatment outcomes in 421 patients from
Trial 204, 24 months post-randomization. Taken together,
the results of these trials show that joint treatment of MDR-
TB patients with an optimized background regimen (BR) of
anti-tuberculosis drugs and Deltyba significantly improved
the two-month sputum culture conversion (SCC) rates,compared to a BR plus placebo. In addition, 6-month
Deltyba treatment was associated with a more highly
favorable long-term treatment outcome and lower mor-
tality as compared to 2 month placebo or Deltyba [8].
Most recently, a cost analysis of the burden of MDR-/
XDR-TB in Germany based on the respective strain resis-
tance patterns reported to the National Reference Center
for Mycobacteria was published [9]. There, the actual
direct medical costs of suitable therapies and the indirect
costs of MDR-TB were calculated. The results e shown in
the following subsections “Cost of treatment” and “Cost of
productivity loss” e as well as the results of Otsuka’s Trial
204 provided the basis for our study to investigate the cost-
effectiveness of introducing Deltyba in terms of quality
adjusted life year (QALY) gained by comparing different
willingness-to-pay (WTP) thresholds.Methods
Model approach
We developed a dynamic, stochastic, cohort-based Markov
model simulating the long-term costs and effectiveness
parameters of newly diagnosed, adult German MDR-TB pa-
tients for both alternatives (BR with and without adding
Deltyba for 6 months) over a time horizon of 10 years.
Following the recommendations of the Panel of Cost-
effectiveness in Health and Medicine [10] the comparative
performance of the 2 different strategies was calculated by
dividing the incremental costs, i.e. the difference between
the sums of the costs of each treatment over the 10-year
period, with the incremental effectiveness of these in-
terventions. The primary outcome of the analysis was in-
cremental costs per QALY gained to yield a net cost
required to increase by 1 QALY compared with the next less
costly intervention. Secondary outcomes included the in-
cremental costs per disability-adjusted life years (DALYs)
avoided, which is generally used by the WHO for evaluation
effectiveness in developing countries. Negative numbers
will identify cost savings (i.e., if an intervention costs less
and is more effective than its comparator), while positive
numbers indicate additional expenditure per outcome unit.
That means that the higher the ratio, the less cost-
effective the intervention. Each outcome was calculated
based on the expected state occupancies through each
cycle at the end of a given cycle of a fixed one year-period.
Future costs, QALYs, and DALYs were discounted at an
annual rate of 3% with varying discount rates in sensitivity
analyses. As commonly used, a rough benchmark of $50,000
per QALY, i.e., currently about V37,000 per QALY, as WTP
was considered to be the outer range in which an inter-
vention is assumed to be cost-effective. The
634 R. Diel et al.epidemiological characteristics of the 65 MDR-TB/XDR-TB
patients reported to the German Robert Koch Institute in
2012 were used for calculating the remaining life expec-
tancy in each cycle and for creating distributions to
calculate DALYs as described below.
Base case simulations were performed from the societal
German perspective including both direct costs arising for
the Public Health Insurances well and costs due to loss of
productivity. Simulations were performed with the TreeAge
Pro 2014 Healthcare Module (TreeAge Software Inc; Wil-
liamstown, MA) and version 6 of @risk (Palisade Corp;
Middlesex, UK).Model structure and clinical data
Patients with MDR-TB or XDR-TB started a planned treat-
ment period of 24 months when participating in the ran-
domized placebo controlled Trial 204. The model structure
was determined by the core outcomes assessed in the
registry Trial 116 at the end of their 24-month MDR-TB
therapy.
The estimate of incremental cost-effective analysis was
performed accordingly by comparing the outcomes be-
tween patients that participated in the open-label Trial 208
and received additional 6-month Deltyba treatment with
patients not participating in Trial 208 and therefore
receiving only 2 months or no Deltyba treatment. The raw
data from the results of both regimens collected in Trial 116
were normalized in the model to a hypothetical cohort size
of 1000, on average 38-year-old MDR-TB/XDR-TB patients
according to the data obtained from the Robert Koch
Institute (RKI) in 2012 [9]. After 2 years, patients were
classified with their respective proportions into one of the
following four health states as defined by the WHO (see
Table 1):
- Treatment success: “Cure” (five consecutive negative
cultures from samples collected at least 30 days apart in
the final 12 months of treatment) or “Treatment
completed” (MDR-TB patients who completed treatment
according to program protocol but did not meet the
definition for cure because of lack of bacteriological
results)Table 1 Results of MDR-TB treatment in Trial 204 (Trial 116).
Treatment outcome MITT solid total N Z
BR (placebo or dela
Consent to trial 116
Favorable treatment outcome 126 (55.0%)
Unfavorable treatment outcome 103 (45.0%)
Cured 111 (48.5%)
Treatment completed 15 (6.6%)
Failed 26 (11.4%)
Defaulted 58 (15.3%)
Died 19 (18.3%)
MDR-TB Z multidrug resistant tuberculosis; MITT Z modified intent-- Treatment failure (“Failed”)
- Lost to follow-up (“Default”)
- Death due to TB.
In our simulation, the time horizon for evaluating asso-
ciated costs and outcomes was extended for a further 8
years to fulfill a chosen total of 10 years which were divided
into equal one-year increments. During the 2 years of MDR-
TB treatment, all deaths are regarded as caused by TB,
using the respective probabilities for mortality as a result of
Trial 204 when adding or not adding Deltyba (tpDcm_D or
tpDcm_noD, see Table 2). MDR-TB/XDR-TB patients
achieving “treatment success” with or without a full course
of Deltyba are assumed to live and die in the years
following MDR-TB treatment from background mortality
only according to age- and gender-dependent life expec-
tancy as established for the general population, with a
probability (tpDn) recalculated in each cycle. In order to
avoid overestimation of mortality among MDR-TB patients,
background mortality was assumed to be included in the
TB-associated probabilities of mortality and was not pre-
sented separately.
Once patients are classified as “failed” or “defaulted”,
they remain in this state for the rest of those 10 years and
cannot experience treatment success anymore. Patients
who failed received a palliative regimen afterwards in both
cohorts, as long as they survived, for the remainder of the
10 years. They were assumed to have the same probability
of dying from TB in a given year as the patients who were
treated during the first two years of the Trial 204. As failed
MDR-TB patients were not expected to differ in the
Deltyba  6 months or Deltyba  2 months group after 2
years, the probability of dying from TB under the BR-
regimen (tpDcm_noD) was used for patients of both cohorts
in order to prevent any bias in favor of the Deltyba  6
months group.
Patients who are lost to follow-up without any medica-
tion may experience a higher rate of mortality
(tpDcm_default) than patients who fail to complete treat-
ment but received palliative care. Therefore e although we
used the same probability of mortality for defaulted pa-
tients as for patients with treatment failure in base case
analysis (see Table 3) e we increased in our sensitivity
analysis the range of their annual probabilities of dying421
manid  2 months) Delamanid  6 months
N Z 229 Consent to trial 116 N Z 192
143 (74.5%)
49 (25.5%)
110 (57.3%)
33 (17.2%)
32 (16.7%)
15 (7.8%)
2 (1.0%)
to-treat.
Table 2 Input variables for cost effectiveness analysis.
Variables category Distributiona Value Reference
Starting age of cohort (mean) Fixed 38 yrs [9]
Total cost of treatment (Deltyba plus BR) Fixed V77,922.61 [9]
Total cost of treatment (BR-only) Fixed V68,201.10 [9]
Loss of productivity (24 weeks) given treatment success Lognormal V17,721.60 [9]
Loss of productivity per year Lognormal V26,951.60 [9]
Market price for Deltyba Lognormal V25,200 According
to manufacturer’s info
Probability of cure (Deltyba plus BR) Fixed 0.573 Trial 204
Probability of cure (BR-only) Fixed 0.4845 Trial 204
Probability of treatment completed (Deltyba plus BR) Fixed 0.172 Trial 204
Probability of treatment completed (BR-only) Fixed 0.0655 Trial 204
Probability of failure (Deltyba plus BR) Fixed 0.653 Trial 204
Probability of failure (BR-only) Fixed 0.252 Trial 204
Probability of default (Deltyba plus BR) Fixed 0.306 Trial 204
Probability of default (BR-only) Fixed 0.563 Trial 204
Probability of mortality (BR-only), tpDcm_noD Fixed 0.1844 Trial 204
Probability of mortality (Deltyba plus BR), tpDcm_D Fixed 0.0408 Trial 204
Probability of mortality after default, tpDcm_default Fixed 0.1844 Assumption
Cost of palliative care Lognormal V17,113.07 Calculated
Probability of secondary cases by transmission (per year) Beta 0.03 [9]
Utility during intensive treatment Beta 0.58 [13]
Utility during continuous treatment Beta 0.68 [14]
Utility following treatment failure Beta 0.68 Assumption
Utility following default Beta 0.58 Assumption
Utility following treatment completed or cure Fixed 1 Assumption
a In probabilistic sensitivity analysis.
Cost-effectiveness of adding Deltyba for MDR-TB treatment 635from MDR-TB (up to 50%). A simplified decision tree is
depicted in Fig. 1.
Patients who achieve sputum culture conversion may
experience a subsequent relapse defined as a switch from a
negative to a positive sputum culture status over the course
of a treatment program. However, no data specific for
Deltyba were available in the Trial 204 during the 2 years
of monitoring, and also no published relapse data are
available for MDR-TB patients in Germany. Accordingly,
relapse of TB could not be considered as a comparative
outcome between the two treatment options in the model.
In addition, patients who had reached the “treatment
success” state were assumed to be free from exposure to
the risk of relapse during the following years.
Patients who were lost to follow-up were assumed not to
exhaust any further healthcare resources regarding treat-
ment of MDR-TB/XDR-TB. As with patients who died, no
additional costs were assigned to them for the remaining
years in the model. Patients lost to follow-up were assumed
to suffer permanently the same reduction in quality of life
as patients at the start of treatment, thus the lowest utility
of 0.58 per remaining life year (see below) was assigned to
them.
Transmission dynamics
Most transmission of MTB infections to contact persons of
an infectious TB patient is thought to occur prior to diag-
nosis and beginning of treatment; it will as a rule be halted
by established precautionary procedures such as initialisolation in hospital and the wearing of masks. We assumed
that the foregone incidence of MTB infections was the same
at the onset of the treatment alternatives, and that further
spread of MTB would only differ as a function of the
respective proportion of defaulting patients without access
to second line drugs. These remain continuously infectious.
Estimating that the annual risk of progression of recently
infected contact persons to active TB is at least 0.3%
[11,12] and given that a typical MDR-TB patient on average
transmits LTBI to 10 contacts per year of infectiveness, 0.03
new secondary cases of MDR-TB may be produced per year
in treatment defaulters. We collected the resulting costs in
base-case analysis. As that figure may, however, substan-
tially differ depending on the number of the contacts and
on the degree of infectiousness, it was subjected to sensi-
tivity analysis including zero infected contacts.
Costs
Inpatient and outpatient cost, which include treatment
monitoring, weighted drug costs already tested for
different BR treatment options, unit cost for Deltyba and
indirect costs were gathered. According to data received
from the RKI for 2012, 57 of 65 MDR-TB patients were
hospitalized (87.69%) and accrued hospital care costs for an
average 89 days, after which they received ongoing sec-
ondary outpatient care until completion of the recom-
mended 20 months’ treatment [9]. All costs were estimated
using figures for the year 2013, and are reported in
Euro (V).
Table 3 Result of base case and univariate sensitivity analysis.
Base case analysis Treatment Cost per patient (V) Effectiveness gained Incremental cost per
incremental effectiveness unit
QALY gained Deltyba plus BR 142,731.96 8.47 Dominates (V3494)
BR-only 150,908.69 6.13
DALY avoided Deltyba plus B 142,731.96 7.26 Dominates
(V1825 per DALY avoided)BR-only 150,908.69 11.74
Parameter varied Variation Treatment Cost per
patient (V)
QALYs
gained
Incremental cost
per incremental QALY
Probability of dying
from MDR-TB after default
þ20% Deltyba plus BR 141,852.49 8.45 Dominates (V2607)
BR-only 148,052.01 6.07
þ50% Deltyba plus BR 140,751.37 8.43 Dominates (V1534)
BR-only 144,475.40 6.00
Cost of palliative care
after failure
þ20% Deltyba plus BR 144,979.28 8.47 Dominates (V3803)
BR-only 152,133.06 6.13
20% Deltyba plus BR 140,484.64 8.47 Dominates (V3190)
BR-only 149,378.22 6.13
Secondary cases due
to transmission per year
0.00 Deltyba plus BR 142,102.00 8.47 Dominates (V2891)
BR-only 148,862.48 6.13
0.06 Deltyba plus BR 143,361.92 8.47 Dominates (V4102)
BR-only 152,954.90 6.13
Discount rate 0% Deltyba plus BR 146,744.60 8.03 Dominates (V7346)
BR-only 156,070.46 6.76
6% Deltyba plus BR 139,330.62 9.04 Dominates (V2099)
BR-only 146,553.27 5.61
Market price for Deltyba þ20% Deltyba plus BR 145,430.64 8.47 Dominates (V2343)
BR-only 150,908.69 6,13
20% Deltyba plus BR 140,038.28 8.47 Dominates (V4651]
BR-only 150,908.68 6.13
Disutility for living with MDR-TB Utilities set to 1
(no disutility)
Deltyba plus BR 142,731.96 8.41 (LYG) Dominates (V3866)
BR-only 150,908.69 6.30 (LYG)
Time horizon 20 years Deltyba plus BR 149,233.42 17.54 Dominates (V1430)
BR-only 159,272.05 10.52
Probability of treatment
success when adding Deltyba
þ10% Deltyba plus BR 128,974.95 8.93 Dominates (V9976)
BR-only 156,908.69 6.13
10% Deltyba plus BR 156,488.97 8.01 V2974/QALY gained
BR-only 150,908.69 6.13
Payer perspective No loss
of productivity
considered
Deltyba plus BR 89,789.18 8.47 V5084/QALY gained
BR-only 77,899.66 6.13
All costs reported in 2013 Euros.
QALYs: quality adjusted life-years; DALYs: disability adjusted life-years; LYG: life year gained; BR: background regimen; TB:
tuberculosis.
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As recently published [9], the total treatment costs of MDR-
TB weighted according to the strain resistance patterns of
MDR-TB patients in 2012, amounted to V64,429.23. The
mean weighted costs for medication as BR for primary
outpatients or after initial hospitalization were V51,113.23
and V38,440.00, respectively. The mean reimbursement for
hospital treatment was V26,000.76, whilst the costs of
diagnosing and monitoring MDR-TB cases as primary out-
patients amounted to only V2192.13. Costs of monitoring
MDR-TB patients following hospitalization and until end of
treatment were even lower with V1550.04.In Germany, costs of administering Deltyba amount to
V25,200 per full course of 168 days (188 tablets a´ 50 mg). In
cases where MDR-TB patients were treated as primary
outpatients, these costs have to be added in full to the
figure of V51,113.23, increasing it to V76,313.23. The costs
due to administering Deltyba following initial hospitali-
zation (168 days minus 89 days of hospital stay Z 79
remaining days) were calculated as follows: V37.50 (price
per tablets)  4 tablets  79 days Z V11,850. This figure
has to be added to the V38,440.00 as stated above,
increasing it to V50,290.00.
The total costs for treating MDR with a BR plus Deltyba
are accordingly: ([V76,313.23 þ V2192.13]  0.1231)
Cost-effectiveness of adding Deltyba for MDR-TB treatment 637þ ([V50,290.00 þ V1550.04 þ V26,000.76]  0.8769)
Z V9664.00 þ V68,258.60 Z V77,922.61.
As 156 of 229 patients in trial 116 did not receive pla-
cebo, but Deltyba up to 2 months at the start of the 20
month MDR-TB treatment course, treatment costs for the
BR-only group have to be weighted accordingly, resulting in
a figure on total costs for the BR-only group of V68,201.10.
Routine data on the frequency and severity of possible side
effects of MDR-TB treatment and the resulting adjuvant
medicationor procedures are at thiswriting not available, thus
the respective costs were not included in our calculations.
The most serious side effect of Deltyba, QT prolonga-
tion, may lead to heart rhythm disorders such as ventricular
tachycardia. No clinical events, however, have yet been
reported as resulting from such prolongation. Studies to
determine whether QT-prolongation due to moxifloxacin
and clofazimine treatment in combination with Deltyba
leads to additive effects on heart rhythm or whether the
drugs can safely be used together are also inexistent.
Consequently, no costs regarding side effects of Deltyba
were considered in the cost-effectiveness analysis.
Cost of palliative care
For practical purposes, the costs of palliative care following
treatment failure are the respective drug costs for the BR
minus the costs of injectable group 2 drugs plus costs for
outpatient care. Thus, the costs of palliative care are
V51,113.23 plus V2192.13 minus the cost for the least
expensive injectable drug amikacin (V16,842.24 plus V7908),
amounting to a total of V28,555.12 per 20 months. Normal-
ized to 12 months, the costs add up to V17,113.07 per year.
Cost of productivity loss (indirect cost)
In accordance with the human capital approach, the
weighted productivity loss per day for TB patients was
established atV73.84 [9]. That figure has to bemultiplied by
the estimated number of days off work. In base case we
restricted the sick leave duration to the intensive phase of
240 days for those patients who achieved treatment success;
in this case the indirect costs amount to: V17,721.60
(V73.84  240 days). In contrast, in the case of treatment
failure and default and death, thewhole 2 years (730 days) of
observation must be taken into account (V53,903.20), and
then productivity loss of each additional year (V26,951.60).
Health utilities for QALYs and disability
weights
Utility weights for assessing QALYs were taken from two
studies, of which only one reported EuroQol (EQ-5D) based
utility weight that could be applied within the health state
structure of the model:
For weighting the quality of life of MDR-TB patients in
the 8 month-intensive phase of treatment, which is domi-
nated by physical health impairment and discomfort from
invasive medical investigations, the utility of 0.58 as re-
ported in a study by Resch et al. [13] was used. The utility
of 0.58 was assumed equal to that of patients lost to follow-up, under the assumption that they were left untreated
again and increasingly suffered from severe TB symptoms.
After finishing the intensive phase the utility for regularly
treated patients was assumed to increase by 10 percentage
points to 0.68, according to Guo’s review [14], for the
continuous phase of MDR-TB. The combined total utility for
the treatment period of 24 months was weighted between
the utilities for the intensive and continuous phase ac-
cording to the time spent in the two phases.
The quality of life of MDR-TB patients who had passed
the intensive phase but finally failed therapy and subse-
quently received palliative treatment was assumed equal
to patients in the continuous phase with a utility of 0.68. No
disutility was provided for treatment success (cure or
treatment completed) after 2 years, thus a utility of 1
(100%) was linked with the life years gained of successfully
treated MDR-TB patients in the following years of the time
horizon. For XDR-TB utilities the same utility values iden-
tified for patients with MDR-TB were used, because XDR-
therapy does not necessarily differ from MDR-TB.
DALYs are the sum of the present value of future years of
lifetime lost through premature disability (YLL), and the
years lost by the disease by weighting the time spent with
the disease by its average severity (YLD). The disability
weight for TB of 0.331, which does not differ between
different states nor between TB and MDR-TB, was sourced
from the latest global burden of disease study reported by
Salomon et al. [15]. The disability weight changed again to
zero (i.e. to non-disability) after treatment completion. In
our model, the calculation of DALYs followed the approach
detailed by Fox-Rushby and Hanson [16] and Diel and
Lampenius [17]. Age, gender and the age of TB-related
death were taken from the 65 MDR-TB patients reported
to the RKI in 2012 for creating distributions around epide-
miological averages coupled with a Monte Carlo simulation
for 1000 MDR-TB patients to address uncertainty.Sensitivity analysis
Deterministic sensitivity analysis was performed to prove
robustness of outcomes, varying input variables along their
reasonable ranges. With respect to QALYs we assessed the
impact of extending the initially chosen time horizon of the
mode to 20 years. We varied several cost parameters and
the market price of Deltyba by 20%, set all disutility
weights to zero, doubled the discount rate from 3% to 6% or
set it to zero and also removed loss of productivity. Also,
the probability of dying for untreated patients lost to
follow-up was increased by 20% and 50%. As the probabili-
ties of treatment success are important variables for
determining incremental cost-effectiveness, we varied the
fixed probability of treatment success when adding
Deltyba by 10% and performed a threshold analysis for
calculating the probability level below which the Deltyba
regimen should not fall in order to dominate the BR-only-
regimen. Furthermore, in order to capture the interactions
between multiple inputs we provided a probabilistic
sensitivity analyses (PSA) by assigning an appropriate sta-
tistical (probability) distribution for all parameters that
were not fixed values. We then ran the model a large
number of times in a Monte Carlo simulation. Thus an
Figure 1 Markov cohort decision tree of the cost-effectiveness model. Simplified Markov model for predicting the total costs and
the occurrence of deaths from MDR-TB. A decision node (,) is the decision to add or not to add Deltyba to a background regimen
(BR) for a cohort of 38-year-old MDR-TB patients. Branches from a Markov node (M) represent the possible different health states.
Branches from a change node (B) represent the possible outcomes of an event. A terminal node (=) represents a state from which
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Cost-effectiveness of adding Deltyba for MDR-TB treatment 639estimate of the joint parametric uncertainty of both in-
cremental costs and effectiveness was provided, allowing
us to determine the probability of how often Deltyba plus
BR could be considered cost-effective versus the BR alone-
strategy at various WTP-thresholds. Input parameters are
shown together with their probabilistic distributions in
Table 2 and the univariate variations of the respective pa-
rameters in Table 3.
Results of the base case model
Following a 10-year time horizon, the total discounted costs
per MDR-TB/XDR-TB-patient who had been treated with
Deltyba for 6 months plus BR amounted to V142,732
including costs arising from productivity loss, while during
the same period 8.47 QALYs were gained. In contrast, the
total discounted costs and discounted QALYs for BR alone
were V150,909 and 6.13 QALYs (Table 2). Accordingly, in
base case analysis, the addition of Deltyba proved to be
dominant over the BR alone-strategy by simultaneously
saving V8176.73 and gaining 2.34 QALYs.
Due particularly to the lower number of years of pre-
mature life lost, treatment with Deltyba caused only 7.26
DALYs compared to 11.74 DALYs when using BR alone per
single patient. The incremental cost per DALY avoided with
Deltyba plus BR versus BR alone was on average V1825.
Of note, following the BR-only treatment 378 out of the
cohort of per 1000 MDR-TB/XDR-TB patients had died after
10 years, whilst only 207 died following the Deltyba-plus
regime, saving a total of 155 (15.5% of the cohort) lives
within the period of 10 years.
Results of sensitivity analysis
Deltyba was cost saving in 73% of probabilistic sensitivity
analyses compared to BR alone and 100% cost effective at a
willingness-to-pay (WTP) threshold of V10,000. Cost-
effectiveness remained unchanged when disutilities were
set to zero resulting in a cost-saving of V3866 per life year
gained. Differences in incremental savings brought about
by assuming no secondary MDR-TB cases following in-
fections caused by untreated patients were negligible. In
this case, outperformance of the BR-alone strategy by the
Deltyba plus BR-strategy diminished by only about V3060
per patient over ten years in our cohort of 1000 MDR-TB/
XDR-TB patients but did not significantly change the cost-
effectiveness ranking.
When the probability of treatment success by adding
Deltybaefixed inbasecaseanalysis as a result of trial 204e
was assumed to be 10% lower, i.e. only 67.05% instead of
74.5%, the ICER was V2974 per QALY gained, but clearly
remained cost-effective. Threshold analysis at aWTP of zero
V showed that even when the probability of successfula patient will jump to the next cycle. Only the state “death” i
probability of death due to causes other than MDR-TB (“background
patients receiving no Deltyba (BR-only). tpDm_D: probability of
tpDcm_default: probability of death due to MDR-TB in patients af
chance node’s branches to sum to 1.0).treatment of Deltyba plus-strategy was reduced to 70.1% it
was still cost saving compared to the BR-only strategy.
If the economic perspective was restricted to the public
health insurance, Deltyba plus BR was not cost saving
compared to BR alone but amounted on average to V5084
per QALY gained.Discussion
Only very few incremental cost-effectiveness analyses on
different MDR-TB treatment options have been published,
and those refer to low- or middle-income countries where
routine sputum culturing and drug susceptibility testing is
not always available.
Resch and colleagues [13] evaluated five different
treatment programs for previously treated MDR-TB patients
including DOTS in Peru. There, a DOTS-plus strategy (indi-
vidualized treatment with second-line drugs following drug
susceptibility testing) would be most-effective by pre-
venting 4.8 deaths per 100,000 over a horizon 30 years and
producing incremental costs of $720 per QALY gained
compared to DOTS-alone.
Fitzpatrick and Floyd in their review [19] compared MDR-
TB interventions in Estonia, Peru, Philippines and Russia
(Tomsk Oblast). While the costs of treatment per patient
differed greatly between the regions, the costs per DALY
averted were lowest at $163 in Peru where outpatient care
using a standardized regimen without drug testing was
principally employed.
Onbehalf of theWHO,Vassal performedapreliminary and
officially unpublishedWHO “exploratory” cost-effectiveness
analysis on the practice of adding Sirturo [20] to the MDR-
TB treatment regimen in six low to middle-income coun-
tries (China, Estonia, Nepal, Philippines, Peru and Russia).
Although the time horizon of the study was restricted to a
period of only 20 months Sirturo plus BR was considered to
be cost-effective compared to a BR-alone strategy.
The results of our study indicate that Deltyba is
generally cost-effective in the current German setting
when compared to BR alone. From the societal perspective,
Deltyba dominates (incurs more benefits at lower costs)
the BR comparator in terms of incremental cost per QALY in
71% of all probabilistic assumptions as shown in Table 3.
This result was also mirrored for the incremental cost per
DALY avoided. Use of Deltyba leads to a higher number of
patients achieving treatment success, which translates into
savings on indirect costs and costs for palliative care
following treatment failure. The savings gained by using
Deltyba outweigh the increased drug acquisition costs
associated with its full use of 24 weeks.
From the payer-perspective only, Deltyba treatment is
not cost-saving using the German list price for Deltyba of
V25,200 per course, but is still clearly cost-effective, evens an absorbing one from which departure is excluded. tpDn:
mortality”). tpDm_noD: probability of death due to MDR-TB in
death due to MDR-TB in patients receiving Deltyba plus BR.
ter default. #: Complementary probability (all probabilities of
640 R. Diel et al.if the lower threshold for cost-effectiveness of £20,000
(currently equivalent to about V25,093) as requested by
NICE [18] was proposed.
As our model was only based on the patient-level data
representing the outcomes of Otsuka’s trial 204, it has some
limitations. There were MDR-TB patients solely from
outside of Germany enrolled; their treatment outcomes
cannot be directly compared to those of the German MDR-
TB population. For example, treatment success of MDR-TB
patients under standard of care-treatment in Germany re-
ported for 2012 [21] was higher with 63% than the 55% of
patients without Deltyba in Trial 204, but it must be
considered that in such small study populations e here
NZ 65 MDR-TB patients e minimal numerical changes may
have important impact on percentages.
Secondly, we did not include the costs associated with
relapse (reversion) following sputum culture conversion, a
parameter that was not monitored in Trial 204. In the
Sirturo C208 trial, however, a relapse was shown in only 4
of 66 patients in the bedaquiline arm compared to 10 pa-
tients suffering from relapse in in the equally large placebo
group [22]. Assuming a similar risk reduction for Deltyba,
cost-effectiveness of adding Deltyba in our study may be
underestimated.
A third limitation is the assumption that patients who
were once lost to follow-up remained lost over the com-
plete time horizon of the analysis and did not gain specific
MDR-TB treatment at a later date. An audit of initially-lost
TB patients between 2004 and 2008 in West Yorkshire in the
UK reported that 16% of patients recommenced treatment
within a period between 12 and 24 months after starting
therapy, but this observation did not refer to MDR-TB [23].
Therefore, the proportion of MDR-patients in Germany with
eventual re-treatment and the resulting outcomes must yet
be evaluated from future TB surveillance data.
The model also expects, for both outcome parameters e
QALYs as well as DALYs e that patients who achieved
treatment success did not experience any lasting disutility
(in terms of quality of life) or disability (in terms of
calculation of DALYs). Although this is probably an overly
optimistic assumption with respect to eventual TB sequelae
[24] the impact of differences in utility weights assigned to
the respective health states on outcomes in our study was
limited, showing cost effectiveness of adding Deltyba
even if quality of life was considered 100% in sensitivity
analysis for all life years counted in the model over the time
horizon.
In Germany, Deltyba plus BR can be shown to be a
likely dominant strategy versus BR alone, when taking loss
of productivity into consideration. Although the number of
MDR-/XDR-TB patients in Germany in 2012 is relatively
limited, no data were available with respect to the real
time of sick leave days on an individual basis. As it can
hardly be assumed that MDR-TB patient is fully capable of
working for an average of 8 h a day under the difficult
conditions that taking injectable drugs twice daily creates,
we used the recommended period of 8 months for admin-
istering injectable drugs as the period of sick leave days.
This conservative approach, however, may underestimate
the true number of sick leave days. If we assume that
impairment caused by the disease itself and the probable
side-effects of the other drugs that have still have be takenbeyond that period, productivity would continue to be
drastically reduced. Of note, the CDC recently considered
indirect cost for the full treatment period of at least 20
months to amount to USD 126,000 [25].
Trial 204 was not designed as a pivotal study, so the
effects of adding Deltyba to BR are currently being
investigated in greater depth, under Trial 213. There, the
exact dates of default and death will be addressed as well
as relapses within a period of one year after finishing the
MDR-TB treatment. Of even more importance is finding an
answer to the question of whether sputum smear culture
conversion occurs earlier with Deltyba and if in thus-
treated patients the total treatment duration may be
shortened. The results of that trial may be considered in
future model simulations.
In conclusion, the results of our analysis show that
treatment with Deltyba for 24 weeks added on to a five-
drug BR is cost-saving in 73% of all probabilistic assumptions
from a societal perspective compared to BR alone, even
with a 20% increase of its current market price. These re-
sults strongly support the application of Deltyba in
treating MDR-TB patients.Conflict of interest
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